KabuDo

NASDAQ: ISRG · Health Care Equipment

Intuitive Surgical

Intuitive Surgical, based in Sunnyvale, California, makes the da Vinci robotic surgical systems and the Ion endoluminal system for lung biopsies. Hospitals buy or lease the systems, then buy instruments and accessories for every procedure and pay for service. In 2025 instruments and accessories brought in $6,019 million of revenue, systems $2,474 million and service $1,572 million; total revenue rose 21% to $10,065 million and net income was $2,856 million (diluted EPS $7.87). da Vinci procedures grew about 15% in 2025, and the newest da Vinci 5 had an installed base of 1,231 systems at year-end. It has no borrowings on its balance sheet and buys back stock. In October 2026 it agreed to pay $450 million to settle a hospital antitrust class action over instrument service and repair.

Last updated

Analysis last edited: October 25, 2026 · Financial data fetched: October 25, 2026 14:17 (SEC EDGAR) · Source 10-K filed: February 3, 2026

Built on10-K FY2025 · filed 2026-02-0310-Q (quarter ended 2026-09-30) · filed 2026-10-21Proxy statement (2026)

Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.

01

At a glanceFrom SEC data

Eight headline measures, each placed among the companies covered on this site.

Revenue growth
18.2%

Higher than 85% of 372 non-financial companies

Average yearly growth over the years shown

Operating margin
29.3%

Higher than 81% of 311 non-financial companies

Latest fiscal year (FY2025)

ROIC minus WACC
+4.3 pts

Higher than 54% of 311 non-financial companies

Return on capital above (or below) its estimated cost

Net debt ÷ EBITDA
-1.7x

Higher than 5% of 304 non-financial companies

Below 0 means more cash than debt

Cash conversion
1.06x

Higher than 13% of 349 non-financial companies

Operating cash flow ÷ net income

Dividend raises
—

Years the dividend per share rose, of the last 5

P/E today
57.4x

Latest close 2026-11-04; trailing 12 months to 2026-09-30

Beta
1.07

Above 1 = moves more than the market

Each marker shows where this company sits among the non-financial companies covered on this site, not all listed companies (left = lowest, right = highest). A high position is not automatically good — for net debt ÷ EBITDA, higher means more debt. Details and formulas are in the sections below and in How to read this.

02

Valuation todayFrom SEC data

Price-based measures at the latest close, next to the same measures at the last fiscal year-end.

Share price$478.00close on 2026-11-04

Market cap$169.74B

P/E today
57.4x

At FY2025 year-end: 72.0x

Earnings: trailing 12 months to 2026-09-30

P/B today
9.5x

At FY2025 year-end: 11.3x

Book value at FY2025 year-end

EV/EBITDA today
46.2x

At FY2025 year-end: 55.8x

EBITDA for FY2025

FCF yield today
1.5%

At FY2025 year-end: 1.2%

Free cash flow for FY2025

Dividend yield today
—

Dividends per share for FY2025

“Today” uses the latest closing price (2026-11-04, Yahoo Finance daily closing prices) and shares outstanding at the last fiscal year-end. The rest of this page — including the financial table and ROIC vs. WACC — uses fiscal year-end prices. These are reference figures, not a judgment of whether the stock is cheap or expensive.

03

What changed since last earningsFrom SEC data

The latest reported quarter against the same quarter a year earlier, the balance sheet against the previous quarter-end, and what management said in its latest earnings release.

Quarter ended Sep 30, 2026.

  • Revenue↑ +21.7%$2.51B → $3.05B (vs. a year earlier)
  • Operating margin↓ −10.9 pts30.3% → 19.4% (vs. a year earlier)
  • Net income↓ −25.8%$704M → $523M (vs. a year earlier)
  • Diluted EPS↓ −23.6%$1.95 → $1.49 (vs. a year earlier)
  • Cash↑ +7.9%$2.76B → $2.98B (vs. previous quarter-end)

Source: Form 10-Q ↗ (SEC XBRL). Long-term debt is the tagged long-term debt figure and leaves out short-term borrowings.

From the earnings release of Oct 20, 2026.

Key changes

  • Q3 revenue $3.05B, up 22%. Source sentence
    Third quarter 2026 revenue of $3.05 billion increased 22%, compared with $2.51 billion in the third quarter of 2025.
  • Procedures up about 15%. Source sentence
    Worldwide procedures (da Vinci and Ion combined) grew approximately 15% compared with the third quarter of 2025.
  • Net income included a $450M pre-tax charge. Source sentence
    Third quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. included a pre-tax charge of $450 million in connection with the settlement of previously disclosed antitrust class action litigation.

Written by AI. A line appears only if its figures and direction match the quoted sentence, which an automatic check confirms. Companies' outlooks are their own and may not be met. Read the release ↗

04

Company profileFrom SEC dataShow

Legal name
INTUITIVE SURGICAL INC
Headquarters
SUNNYVALE, CA
Incorporated in
Delaware
Fiscal year end
12/31
Exchange & ticker
NASDAQ: ISRG
Industry
Health Care Equipment
CIK
1035267

Workforce (as of FY2025 year-end)

  • Employees

    17,021

Source: Form 10-K (FY2025) cover page and business description

05

Earnings calendarFrom SEC dataShow

When the company reports each quarter: the quarter-end date, the day results were released, and when the 10-Q or 10-K was filed.

Next report

Q4 FY2026

Quarter end: December 2026. In past years, Q4 results were released 22–23 days after quarter end (Jan 22, 2026; Jan 23, 2025; Jan 23, 2024). No date has been announced in the sources this site uses.

Reporting pattern

  • Fiscal year ends around December 31.
  • Reports four times a year: three quarterly reports (10-Q) and an annual report (10-K) for Q4.
  • Earnings releases came 16–23 days after quarter end over the last 12 quarters.
QuarterQuarter endedEarnings release (8-K)Report filed (10-Q / 10-K)
Q3 FY2026Sep 30, 2026Oct 20, 2026 (+20 days)Oct 21, 2026 10-Q (+21 days)
Q2 FY2026Jun 30, 2026Jul 16, 2026 (+16 days)Jul 21, 2026 10-Q (+21 days)
Q1 FY2026Mar 31, 2026Apr 21, 2026 (+21 days)Apr 22, 2026 10-Q (+22 days)
Q4 FY2025Dec 31, 2025Jan 22, 2026 (+22 days)Feb 3, 2026 10-K (+34 days)
Q3 FY2025Sep 30, 2025Oct 21, 2025 (+21 days)Oct 22, 2025 10-Q (+22 days)
Q2 FY2025Jun 30, 2025Jul 22, 2025 (+22 days)Jul 23, 2025 10-Q (+23 days)
Q1 FY2025Mar 31, 2025Apr 22, 2025 (+22 days)Apr 23, 2025 10-Q (+23 days)
Q4 FY2024Dec 31, 2024Jan 23, 2025 (+23 days)Jan 31, 2025 10-K (+31 days)
Q3 FY2024Sep 30, 2024Oct 17, 2024 (+17 days)Oct 18, 2024 10-Q (+18 days)
Q2 FY2024Jun 30, 2024Jul 18, 2024 (+18 days)Jul 19, 2024 10-Q (+19 days)
Q1 FY2024Mar 31, 2024Apr 18, 2024 (+18 days)Apr 19, 2024 10-Q (+19 days)
Q4 FY2023Dec 31, 2023Jan 23, 2024 (+23 days)Jan 31, 2024 10-K (+31 days)

Source: SEC EDGAR filing history. Release dates are the dates the earnings release was furnished to the SEC on Form 8-K (Item 2.02), which is normally the day results are announced. For a quarter whose 10-Q or 10-K isn’t filed yet, the date is the latest Item 2.02 8-K since the previous report, which may be a preliminary or other results-related update. Fiscal years are labeled by the calendar year in which they end.

06

Flagship products & servicesSite analysis

  • Surgical robotics

    da Vinci surgical systems

    Multiport da Vinci systems including the fifth-generation da Vinci 5 (1,231 installed at end-2025) and the single-port da Vinci SP (377 installed).

  • Surgical robotics

    Ion endoluminal system

    Robotic-assisted bronchoscopy for minimally invasive lung biopsy.

  • Surgical robotics

    Instruments and accessories

    EndoWrist instruments, da Vinci stapling and energy products and other accessories used in each procedure.

  • Surgical robotics

    Service

    System service contracts and digital/training offerings.

From the Form 10-K, FY2025.

U.S. and worldwide share of flagship products/services

The 10-K gives no market share figures.

Reviewed: Form 10-K (FY2025) · Form 10-Q (quarter ended 2026-09-30)

07

Recent strategic focusSite analysis

Recent developments.

  1. 2025 results

    Revenue $10,065M (+21%); net income $2,856M; diluted EPS $7.87.

    Source: Form 10-K (FY2025)

  2. Q3 2026

    Revenue $3,049M versus $2,505M; net income $523M versus $704M after a $450M litigation charge; 546 systems placed (335 in the U.S.).

    Source: Form 10-Q (quarter ended 2026-09-30)

  3. Antitrust settlement

    Agreed in October 2026 to pay $450M and accept injunctive relief to settle In re da Vinci Surgical Robot Antitrust Litigation, subject to court approval.

    Source: Form 10-Q (quarter ended 2026-09-30) — Note 8 Commitments and Contingencies

  4. Distribution acquisition

    Acquired the da Vinci and Ion distribution business of ab medica, Abex and Excelencia Robótica on March 1, 2026.

    Source: Form 8-K (2026-03-02) — Item 8.01 acquisition of ab medica distribution business

Capex ÷ D&A (FY2025)

0.90x

Roughly matches depreciation — mostly maintenance/replacement

formulacapital expenditures ÷ depreciation & amortization

e.g.$540M ÷ $600M = 0.90x

termsCapital expenditures (capex) · Depreciation & amortization (D&A)

R&D-to-revenue ratio (FY2025)

13.0%

formularesearch & development expense ÷ revenue × 100

e.g.$1,312M ÷ $10,065M × 100 = 13.0%

termsResearch & development (R&D) · Revenue (net sales)

M&A spend (6-year total)

$97M

Latest year: $14M

Cash-flow-statement spending on acquisitions, net of cash acquired

Where the money goes, over time

Unit: $M. Capex went from $342M in FY2020 to $540M in FY2025

  • Capex
  • R&D
  • M&A spend

formulacapital expenditures ÷ depreciation & amortization

termsCapital expenditures (capex) · Depreciation & amortization (D&A)

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-03

08

Key figures at a glanceFrom SEC data

FY2020–FY2025, 6 years.

Revenue (FY2025)

$10.06B

As reported in the 10-K

Revenue CAGR (5 years)

+18.2%▲favorable

formula(last-period revenue ÷ first-period revenue) ^ (1 ÷ years) − 1

e.g.($10,065M ÷ $4,358M) ^ (1÷5) − 1 = 18.2%

termsCAGR · ^ (exponent) · Revenue (net sales)

Operating margin (FY2025)

29.3%▲favorable

+5.2pt vs. 5 years ago

formulaoperating income ÷ revenue × 100

e.g.$2,946M ÷ $10,065M × 100 = 29.3%

termsOperating income · Revenue (net sales)

ROE (FY2025)

16.7%▲favorable

6-year average: 14.2%

As reported in the 10-K

P/B (FY2025 end)

11.28x

formulafiscal year-end closing price ÷ book value per share

e.g.$566.36 ÷ $50.19 = 11.28x

termsP/B · BVPS

Period-end (fiscal year-end) value, not today's P/B

EV/EBITDA (FY2025 end)

55.8x

formula(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization)

e.g.($201,114M + $0M − $3,368M) ÷ ($2,946M + $600M) = 55.8x

termsEV/EBITDA · Market capitalization · Interest-bearing debt · EBITDA · Depreciation & amortization (D&A)

Period-end (fiscal year-end) value, not today's multiple

  • ▲

    Revenue grew +18.2% a year over 5 years (strong growth)

    From $4.36B in FY2020 to $10.06B in FY2025. The annualized rate (CAGR) makes it possible to compare growth pace across companies of different sizes.

  • ▲

    Operating margin improved: 24.1% → 29.3%

    How much operating profit is left per $100 of revenue. It moved +5.2 points over 5 years — pricing power, cost control, and product mix all show up here.

  • ▲

    Equity ratio is 87.1% (a high level of financial stability)

    The share of total assets funded by equity rather than debt. 50%+ is often read as low bankruptcy risk, though the right level varies by industry (real estate and leasing run lower, for instance).

  • ▲

    Free cash flow was positive in 6 of 6 years

    Operating cash flow minus capital expenditures: the cash left over after funding the business’s own investment, available for dividends, buybacks, acquisitions, or debt paydown. A negative year can mean heavy investment, or weak core earnings — worth distinguishing.

  • ▲

    ROE averaged 14.2% over 6 years (latest: 16.7%)

    How much profit was generated on shareholders’ equity. Roughly 10%+ is often cited as solid for a U.S. company, though this varies a lot by industry and capital intensity.

09

Business modelSite analysis

Places da Vinci and Ion systems in hospitals (sale or lease) and earns recurring revenue from instruments and accessories used in every procedure, plus service contracts.

How money and goods flow at Intuitive Surgical
  1. 01 what it draws on

    Inputs & resources

    • About 17,021 full-time employees (2,288 in R&D, 7,625 in manufacturing)
    • Patents and robotic, imaging and software technology
    • Manufacturing in the U.S. and abroad
  2. 02 what it does

    Activities

    • da Vinci multiport and single-port (SP) surgical systems
    • Ion endoluminal system for lung biopsy
    • Instruments, accessories, stapling and energy products; service and digital tools
  3. 03 who it serves

    Customers

    • Hospitals and surgical centers; less than 10% of revenue through non-U.S. distributors
  4. 04 how money comes in

    How it earns

    • Instruments and accessories $6,019M
    • Systems $2,474M
    • Service $1,572M (2025)

How the business makes money

  • U.S. 68% of 2025 revenue; outside the U.S. 32%.
  • Repurchase authorizations total $13.0B since inception; $4.42B repurchased in the first nine months of 2026.
  • No interest-bearing debt.

Government & regulation around the business

Non-market factors from the company’s filings: what governments and regulators fund, buy, set, approve or restrict, and which part of the flow above each one touches.

Intuitive needs FDA clearance and EU certificates, and faces U.S.–China political risk.

  • Approvals & licenses

    FDA device clearance

    U.S. sales require FDA 510(k) clearance or premarket approval for each device and EU MDR certificates; noncompliance can bring warning letters, recalls or other sanctions.

    Supports and constrainsTouches: Activities

    Source: Form 10-K (FY2025)

  • Trade & export rules

    U.S.–China tensions

    Events between China and the U.S. could disrupt business, including tighter policy or regulatory enforcement.

    Constrains the businessTouches: Customers · How it earns

    Source: Form 10-K (FY2025)

Revenue by segment (FY2025)

Unit: $M — bar length = revenue, (%) = share of total company revenue

  • Instruments and accessories

    6,018.9 (60%)
  • Systems

    2,473.7 (25%)
  • Service

    1,572.1 (16%)

Source: Form 10-K (FY2025) One reportable segment; revenue by type. Total $10,064.7M.

10

Where it earnsSite analysis

Many U.S.-listed companies earn most of their revenue outside the U.S. — this breaks down revenue by country/region so it's clear where the business actually makes its money.

Largest market (FY2025)

United States — 68% of revenue

Revenue by country / region (FY2025)

Unit: $M — bar length = revenue, (%) = share of total company revenue

  • United States

    6,815.8 (68%)
  • Outside the U.S.

    3,248.9 (32%)

Source: Form 10-K (FY2025) Revenue by geography.

11

Contract structureSite analysisShow

Short-term or spot sales carry different earnings quality than long-term or auto-renewing contracts — this shows how the company actually contracts with its customers.

12

Alliances & capital tiesSite analysisShow

Equity stakes, joint ventures, and strategic partnerships disclosed across the 10-K, 8-Ks, and proxy statement.

13

Customers & suppliersSite analysis

Who the company sells to and buys from. Companies rarely name either, so named counterparties come only from the company's own filings and press releases; otherwise this lists the concentration figures the 10-K discloses.

Customers

Hospitals and surgical centers worldwide.

Named by the company

No customer is named as material.

Suppliers

Component and contract manufacturing suppliers.

Named by the company

No single supplier is named as material.

14

Competitors & peersSite analysis

Competitors the 10-K names, and the peer group the company itself chose in its proxy statement. Nothing here is this site's own pick.

Intuitive names Johnson & Johnson and Medtronic as large competitors for stapling, energy and robotic products, and lists companies entering robotic-assisted procedures, including CMR Surgical, Karl Storz, Medicaroid, Distalmotion, Noah Medical and several Chinese firms; it expects increasing competition in China.

Competitors named in the 10-K

Robotic-assisted surgery and bronchoscopy

Source: Form 10-K (FY2025)

Peer group the company chose

2025 compensation peer group (22 companies), from the proxy statement. Peers are companies the board considers comparable — for example when setting executive pay — not necessarily direct competitors.

U.S. medical device, life science tools and technology companies of similar size; Palo Alto Networks, Regeneron, Synopsys and Vertex added; VMware removed.

Source: Proxy statement (2026)

Company names link to this site’s analysis where one exists; “site ↗” opens the company’s own website.

15

Six years of financialsFrom SEC data

Each chart's axis holds a single unit (never mixing dollars, %, and $/share). The table's per-period header links to the filing the numbers came from.

Revenue over time

Unit: $M

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-03

Profit over time (operating → net)

Unit: $M

  • Operating income
  • Pretax income
  • Net income

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-03

Margins over time

Unit: %

  • Operating margin
  • Net margin

formulaoperating income ÷ revenue × 100

termsOperating income · Revenue (net sales)

formulanet income attributable to the company ÷ revenue × 100

termsNet income (attributable to the company)

Cash flow over time

Unit: $M (below zero = cash went out)

  • Operating CF
  • Investing CF
  • Free CF

formulacash flow from operations − capital expenditures

termsFree cash flow (FCF) · Cash flow from operations (operating CF) · Capital expenditures (capex)

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-03

Financial stability & capital efficiency

Unit: %

  • Equity ratio
  • ROE

formulatotal equity ÷ total assets × 100 (as reported in the 10-K)

termsStockholders’ equity · Total assets

formulanet income ÷ average equity (beginning + ending, ÷2) × 100 (as reported in the 10-K)

termsNet income (attributable to the company) · Stockholders’ equity

Earnings per share (EPS) and dividend per share

Unit: $

  • EPS

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-03

Line itemFY202010-K on EDGAR ↗FY202110-K on EDGAR ↗FY202210-K on EDGAR ↗FY202310-K on EDGAR ↗FY202410-K on EDGAR ↗FY202510-K on EDGAR ↗
Income statement ($M)
Revenue4,3585,7106,2227,1248,35210,065
Operating income1,0501,8211,5771,7672,3492,946
Pretax income1,2071,8901,6071,9592,6743,311
Net income (attributable)1,0611,7051,3221,7982,3232,856
Revenue growthcalc(this year’s revenue − last year’s revenue) ÷ last year’s revenue × 100—31.0%9.0%14.5%17.2%20.5%
Operating margincalcoperating income ÷ revenue × 10024.1%31.9%25.3%24.8%28.1%29.3%
Net margincalcnet income attributable to the company ÷ revenue × 10024.3%29.9%21.3%25.2%27.8%28.4%
Balance sheet ($M)
Total assets11,16913,55512,97415,44218,74320,459
Total equity9,75911,95211,11313,39716,53017,942
Equity ratio87.1%87.8%85.1%86.2%87.7%87.1%
ROE10.9%15.8%11.5%14.8%15.6%16.7%
Cash flow ($M)
Operating CF1,4852,0891,4911,8142,4153,031
Investing CF-941-2,4611,371-360-3,273666
Financing CF-8643-2,572-288151-2,364
Free cash flowcalccash flow from operations − capital expenditures1,1431,7509587501,3042,491
Cash and equivalents1,6231,2911,5812,7502,0273,368
Per share & other
EPS ($)2.944.663.655.036.427.87
BVPS ($)27.5633.2731.5537.7746.0850.19
P/E (x)92.877.172.767.181.372.0
EV/EBITDA (x)calc(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization)74.560.648.054.066.055.8
P/B (x)calcfiscal year-end closing price ÷ book value per share9.8910.808.418.9311.3311.28

P/B and EV/EBITDA use each period’s period-end (fiscal year-end) figures, not the current share price. Figures without a "calc" tag are as reported in the Form 10-K (the consolidated financial statements and, for older years, earlier 10-Ks), pulled automatically from SEC EDGAR. Where a later filing restated a prior period, the restated figure is used.

Last 8 quarters

Three-month figures from 10-Q filings. Change is versus the same quarter a year earlier. Newest quarter on top.

Quarter endedRevenueOperating incomeNet incomeDiluted EPS
2026-09-30$3.05B+21.7%$593M-22.0%$523M-25.8%$1.49
2026-06-30$2.89B+18.5%$972M+30.7%$818M+24.3%$2.29
2026-03-31$2.77B+23.0%$855M+48.0%$822M+17.6%$2.28
2025-12-31 †$2.87B+18.8%$864M+17.6%$795M+15.9%—
2025-09-30$2.51B$760M$704M$1.95
2025-06-30$2.44B$743M$658M$1.81
2025-03-31$2.25B$578M$698M$1.92
2024-12-31 †$2.41B$735M$686M—

† Fourth quarter = the 10-K’s annual figure minus the first three quarters; quarterly EPS isn’t derived this way because share counts change during the year.

16

Is ROIC above WACC?From SEC data

ROIC (the return on money invested in the business) above WACC (the cost of raising that money) means the company is creating value. WACC is an estimate, so its assumptions can be adjusted below.

ROIC (FY2025)

15.1%

formulaoperating income × (1 − tax rate) ÷ invested capital × 100 *invested capital = interest-bearing debt + total equity (average of beginning/ending)

e.g.$2,946M × (1 − 11.5%) ÷ $17,236M × 100 = 15.1%

termsOperating income · Effective tax rate · Invested capital · Interest-bearing debt · Total equity

WACC (this site’s estimate)

10.84%

formulacost of equity × equity weight + cost of debt × (1 − tax rate) × debt weight

e.g.Equity weight: $201.11B ÷ ($201.11B + $0) = 100.0%

e.g.Debt weight: $0 ÷ ($201.11B + $0) = 0.0%

e.g.WACC: 10.8% × 100.0% + 5.0% × (1 − 11.5%) × 0.0% = 10.84%

termsCost of equity · Equity weight (E/(D+E)) · Cost of debt · (1 − tax rate) · Debt weight (D/(D+E)) · Market capitalization

ROIC − WACC

+4.3pt▲favorable

Earning more than the cost of capital (ROIC > WACC in 5 of 6 years)

formulaROIC − WACC (positive means the business earns more than its cost of capital)

termsROIC · WACC

How firm is this? With the equity risk premium ±1 point and beta ±0.2, WACC runs 8.9%–13.2% and ROIC − WACC runs +1.9 to +6.3 points. The sign holds across this range. This describes the latest year and does not predict future value creation.

WACC 10.84% is this site’s estimate under the assumptions below (not a figure the company has published)

Risk-free rate
4.95% (10-year Treasury, 2026-11-03)
β
1.07 (price-derived adjusted beta)
Equity risk premium
5.5%
Cost of equity
10.84%
Cost of debt
4.95% (no debt on record, using the risk-free rate)
Tax rate
11.5% (effective rate, FY2023–FY2025)
Capital structure (equity : debt)
100% : 0%
→ Change assumptions and recalculate

ROIC over time, vs. WACC

Unit: % — bars = each period's ROIC, horizontal line = latest WACC. Bars above the line are green, below are red

  • ROIC (above WACC)
  • ROIC (below WACC)
  • WACC 10.84%

formulaoperating income × (1 − tax rate) ÷ invested capital × 100 *invested capital = interest-bearing debt + total equity (average of beginning/ending)

termsOperating income · Effective tax rate · Invested capital · Interest-bearing debt · Total equity

formulacost of equity × equity weight + cost of debt × (1 − tax rate) × debt weight

termsCost of equity · Equity weight (E/(D+E)) · Cost of debt · (1 − tax rate) · Debt weight (D/(D+E)) · Market capitalization

Try different WACC assumptions

β and the equity risk premium are estimates with a real range of plausible values — move the sliders to check whether ROIC > WACC still holds. The risk-free rate starts at the 10-year Treasury yield on 2026-11-03 (U.S. Treasury).

Initial β: 1.07 (price-derived adjusted beta. Raw β 1.10, R² 0.26, 130 weeks)

formula0.67 × β + 0.33 (β = the slope of weekly stock returns regressed on weekly market returns)

e.g.0.67 × 1.105 + 0.33 = 1.071

termsβ (beta)

Period 2024-05-10–2026-11-04, using S&P 500 ETF (SPY) as the market proxy. Source: Yahoo Finance price history.

Cost of equity10.84%

formularisk-free rate + β × equity risk premium

e.g.5.0% + 1.07 × 5.5% = 10.8%

termsCAPM · Risk-free rate · β (beta) · Equity risk premium (market risk premium)

Market value of equity$201.11B

formulafiscal year-end closing price × shares outstanding (= market cap)

termsMarket capitalization · Market value of equity

Interest-bearing debt$0
Cost of debt *no debt on record, using the risk-free rate instead4.95%

formulainterest expense ÷ interest-bearing debt × 100 (clamped to 0–10%; falls back to the risk-free rate if there’s no debt)

termsInterest-bearing debt · Risk-free rate

Capital structure (equity weight : debt weight)100% : 0%

17

What the price implies (DCF)From SEC data

A company's value can be written as its free cash flow divided by (cost of capital − perpetual growth). Working that backwards from the market's valuation shows how much growth the share price assumed — compared here with the company's actual past growth.

Growth the price implies (price on 2026-11-04)

9.3%

Perpetual FCF growth: g = r − FCF ÷ EV = 10.8% − 1.5%

Past FCF growth (FY2020–FY2025)

+16.9%

Compound annual rate, 5 years

Past revenue growth (FY2020–FY2025)

+18.2%

Compound annual rate, 5 years

Inputs (FY2025): free cash flow $2.49B (operating CF − capex); enterprise value $163.8B = market cap $169.74B (latest close, 2026-11-04) + debt $0 − cash and short-term investments $5.93B; r = WACC of 10.8% using this page’s default assumptions (β 1.07, risk-free 5.0%, market premium 5.5%).

Three WACC scenarios

The same calculation under cautious, base and optimistic cost-of-capital assumptions (risk-free rate fixed at the 10-year Treasury yield). Pick one to load it into the sliders below.

Try your own assumptions

V = FCF ÷ (r − g). It starts at the implied growth rate, where the theoretical value equals today’s enterprise value.

Theoretical enterprise value

$166.05B

FCF $2.49B ÷ (10.8% − 9.3%)

Theoretical ÷ actual enterprise value

1.01x

Above 1x: these assumptions value the business above the market did

How sensitive the answer is

Theoretical ÷ actual enterprise value for each combination of r and g.

g \ r8.8%9.8%10.8%11.8%12.8%
0%0.17x0.16x0.14x0.13x0.12x
2%0.22x0.19x0.17x0.16x0.14x
4%0.32x0.26x0.22x0.19x0.17x
6%0.54x0.40x0.32x0.26x0.22x
8%1.90x0.84x0.54x0.40x0.32x

A simplified model for seeing what the market price assumes, not a forecast or a target price. It treats free cash flow as growing at one constant rate forever; the result swings widely with small changes in r and g, and is undefined when g reaches r. Free cash flow here is operating cash flow minus capex, which is after interest — a full DCF of enterprise value would use cash flow before interest. Market cap uses the latest close (2026-11-04) × shares at fiscal year-end; free cash flow and WACC inputs are from the latest fiscal year.

18

Earnings qualityFrom SEC dataShow

The same reported profit can mean different things depending on whether it's backed by cash, driven by the core business, or the result of a one-off item. Four checks below.

  • ✓

    Operating CF ÷ net income: averages 1.14x

    Profit is backed by cash coming in.

  • ✓

    Accrual ratio (latest): -0.9%

    A small share of profit rests on accounting estimates.

  • ✓

    Core-earnings share (operating income ÷ pretax income): 89%

    Most profit comes from core operations.

  • ✓

    Days sales outstanding: 54 → 50 days

    No major slowdown in collecting on sales.

Operating CF vs. net income

Unit: $M — operating CF above net income means profit is backed by cash

  • Operating CF
  • Net income

formulacash flow from operations ÷ net income attributable to the company

termsCash flow from operations (operating CF) · Net income (attributable to the company)

formula(net income − operating CF) ÷ average total assets × 100

termsNet income (attributable to the company) · Cash flow from operations (operating CF) · Total assets

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-03

Profit bridge (FY2025)

Unit: $M — what moved profit from operating income to net income

  • Profit (each stage)
  • Pushed profit up
  • Pushed profit down

formulaoperating income ÷ income before income taxes × 100

termsOperating income · Income before income taxes (pretax income)

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-03

Receivables & inventory days

Unit: days — days grow when receivables or inventory build up faster than sales

  • Days sales outstanding
  • Days inventory outstanding

formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365

termsAccounts receivable · Revenue (net sales)

formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365

termsInventory · Cost of revenue (COGS)

Worked examples (latest period)

formulacash flow from operations ÷ net income attributable to the company

e.g.$3,031M ÷ $2,856M = 1.06x

termsCash flow from operations (operating CF) · Net income (attributable to the company)

formulaoperating income ÷ income before income taxes × 100

e.g.$2,946M ÷ $3,311M × 100 = 89%

termsOperating income · Income before income taxes (pretax income)

formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365

e.g.($1,225M + $1,527M) ÷ 2 ÷ $10,065M × 365 = 50 days

termsAccounts receivable · Revenue (net sales)

formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365

e.g.($1,487M + $1,840M) ÷ 2 ÷ $3,422M × 365 = 177 days

termsInventory · Cost of revenue (COGS)

19

Who holds the sharesFrom SEC dataShow

How much of the stock large institutional investors report owning on SEC Form 13F, how much the directors and executive officers hold (and how much of the vote they control), and roughly how much is left for individual investors. Shown next to beta so the holder mix can be read alongside how much the stock swings.

Institutions, insiders and everyone else, 13F holdings as of 2026-06-30

“Everyone else” is what remains after shares reported on Form 13F and shares held by directors and executive officers: mostly individual investors, plus non-insider families or foundations and smaller or foreign institutions. The figures have different dates and 13F reports count some shares twice — read it as an approximate split.

Held by 13F filers
86.9%
Directors & officers (shares)
0.6%
Everyone else (est.)
12.5%

individuals and other non-13F holders

Directors & officers (voting power)
0.6%

no separate voting figure; shown as shares

Institutional-ownership rank
234 of 416

1 = most institutional; 56% of covered companies have more

Beta (adjusted)
1.07

above 1 = swings more than the market

  • 306.9M shares reported by 2,250 13F filers ÷ 353.3M shares outstanding on 2026-07-16. Option positions are excluded.
  • Directors and executive officers as a group, from the proxy statement’s beneficial-ownership table; includes shares they can acquire within 60 days.
  • A large “everyone else” share can still reflect a family, trust or foundation stake held outside the board; check the proxy statement’s 5% holders.

Sources: SEC Form 13F data set (holdings as of 2026-06-30) · Form DEF 14A filed 2026-03-13 (beneficial ownership table) · Form 10-Q cover page (shares outstanding as of 2026-07-16)

20

Strengths & weaknessesSite analysis

Strengths

  1. 1. Recurring procedure revenue

    Instruments and accessories were 60% of 2025 revenue; procedures grew about 15%.

    Evidence: Form 10-K (FY2025)

  2. 2. Strong growth and margins

    Revenue grew from $4,358M (2020) to $10,065M (2025); operating income $2,946M in 2025.

    Evidence: Form 10-K (FY2025)

  3. 3. No borrowings

    No interest-bearing debt is reported; large buybacks.

    Evidence: Form 10-K (FY2025)

Weaknesses

  1. 1. Antitrust exposure on repairs

    Agreed to pay $450M to settle hospital class actions over instrument service and repair (October 2026).

    Evidence: Form 10-Q (quarter ended 2026-09-30) — Note 8 Commitments and Contingencies

  2. 2. High capital cost for hospitals

    System sales depend on hospital capital budgets.

    Evidence: Form 10-K (FY2025)

21

What draws investors to itSite analysis

Why the stock can look attractive to investors — each point paired with what has to hold for it to stay true, and the opposing view. This is this site's analysis, not a recommendation to buy or sell.

P/E (FY2025)

72.0x

Price at fiscal year-end ÷ diluted EPS

Dividend yield (FY2025)

—

Dividends per share ÷ fiscal year-end price

Payout ratio (FY2025)

—

Dividends per share ÷ diluted EPS

FCF yield (FY2025)

1.2%

(Operating CF − capex) ÷ market cap

  1. 1. Installed base flywheel

    Each new system adds recurring instrument and service revenue.

    What has to hold
    Procedure adoption keeps growing.
    The other side
    Competitors may cut prices.

    Evidence: Form 10-K (FY2025)

  2. 2. Balance sheet

    No reported borrowings; repurchased $4.42B in the first nine months of 2026.

    What has to hold
    Cash flow stays strong.
    The other side
    Litigation costs.

    Evidence: Form 10-Q (quarter ended 2026-09-30)

No interest-bearing debt is reported in Intuitive’s filings, so debt is left blank.

22

ResilienceSite analysisShow

How well the company could absorb a bad year: its financial buffer, how its revenue and profit held up in the worst year on record, and what the 10-K says about the business's exposure to shocks. Figures and filing statements only — no overall rating.

1. Financial buffer (FY2025)

Cash & short-term investments ÷ debt due within a year

—

$5.93B vs. —

Interest coverage (operating income ÷ interest expense)

Not disclosed

Interest expense isn’t reported as a separate line.

Free cash flow ÷ dividends paid

—

2. Worst year in the record, and the recovery

FigureWorst year-over-year changeBack to the prior level?
RevenueNo decline in the record—
Operating income-13.4% in FY2022 ($1.82B → $1.58B)Yes, by FY2024

Covers only the 6 fiscal years on record (FY2020–FY2025), which may not include a full recession — the worst year here isn’t necessarily how the company would fare in a severe downturn.

3. Business resilience (from the 10-K)

  • Profitable every year

    Net income stayed above $1B every year 2020–2025.

    Source: Form 10-K (FY2025)

24

Risks (including geopolitical)Site analysis

Starting from the 10-K's Risk Factors section, organized by category — geopolitical, currency, raw materials, regulatory, disaster, and more — with impact and likelihood assessed by this site.

Risk map

Vertical = impact on results, horizontal = likelihood. Upper right = most severe. Numbers match the list below (placement is this site’s own assessment).

Impact
High
1
Med
35
2
Low
4
LowMedHigh

Likelihood →

"Company disclosure" vs. "this site’s assessment"

The description and mitigation for each risk are this site’s summary of the 10-K’s "Risk Factors" section. Impact and likelihood are this site’s own assessment, not the company’s — where the company discloses its own likelihood assessment, that is noted in the summary.

Impact is judged from how large the affected business is relative to total revenue/profit, and from the risk’s track record of moving results in the past. Likelihood is judged from the filing’s wording and the current business environment (already occurring, or recurring). See the rating criteria.

  1. 1Competition & technology shift

    New robotic competitors

    Company disclosure (summarized from the 10-K)
    Johnson & Johnson, Medtronic, CMR Surgical, Karl Storz, Medicaroid and several Chinese companies are entering robotic surgery; competition in China is increasing.
    Company’s stated mitigation
    Not stated in the filings.
    This site’s assessment
    Impact High / Likelihood High
  2. 2Law & regulation

    Antitrust litigation

    Company disclosure (summarized from the 10-K)
    EndoWrist service/repair suits: $450M class settlement pending approval; SIS case remanded by the Ninth Circuit; Restore appeal pending.
    Company’s stated mitigation
    Not stated in the filings.
    This site’s assessment
    Impact Med / Likelihood High
  3. 3Law & regulation

    FDA regulation and field actions

    Company disclosure (summarized from the 10-K)
    Recalls or field actions could hurt reputation and sales.
    Company’s stated mitigation
    Not stated in the filings.
    This site’s assessment
    Impact Med / Likelihood Med
  4. 4FX & interest rates

    Currency

    Company disclosure (summarized from the 10-K)
    32% of revenue outside the U.S.
    Company’s stated mitigation
    The objective of our hedging program is to mitigate the impact of changes in currency exchange rates on our net cash flow from foreign currency-denominated sales and expenses.
    This site’s assessment
    Impact Low / Likelihood High
  5. 5Costs & inflation

    Tariffs

    Company disclosure (summarized from the 10-K)
    Tariffs and inflation affect costs.
    Company’s stated mitigation
    Not stated in the filings.
    This site’s assessment
    Impact Med / Likelihood Med

25

What changed in the risk factorsFrom SEC data

Paragraphs in the latest 10-K's Risk Factors that have little overlap with the year before, and paragraphs that were dropped.

New or substantially reworded (6)

  • The UK is in the process of overhauling its medical device regulatory framework following its departure from the European Union (“EU”). Read more

    The UK regulatory framework will apply in Great Britain only, as Northern Ireland continues to follow the EU Medical Devices Regulation (“MDR”). New post-market surveillance requirements took effect on June 16, 2025, while a draft of additional rules governing device classification and pre-market approval pathways are expected to be published in 2026. The divergence of the new UK rules from EU law could adversely affect or delay our ability to obtain approval for our medical device products in the UK. In addition, any delays in implementation, changes in interpretation, or additional requirements under the new UK regime could adversely affect our ability to market and service our products in Great Britain, which could have adverse impacts on our…

  • More generally, several governments, including the U.S., have raised the possibility of policies to induce “re-shoring” of supply chains, less reliance on imported supplies, and greater national production. Read more

    Examples include potential “Buy America” requirements in the U.S. If such steps by local governments triggered retaliation in other markets restricting access to foreign products in purchases by their government-owned healthcare systems, the result may have an adverse impact on our business, financial condition, or result of operations.

  • In the U.S., legislation related to AI technologies has been introduced at the federal level and has been enacted by various states. Read more

    At the federal level, in January 2025, the Trump administration rescinded an executive order relating to the safe and secure development of AI technologies that was previously implemented by the Biden administration. The Trump administration then issued a new executive order that, among other things, requires certain agencies to develop and submit to the president action plans to “sustain and enhance America’s global AI dominance,” and to specifically review and, if possible, rescind rulemaking taken pursuant to the rescinded Biden executive order. Additionally, in December 2025, the Trump administration’s “Ensuring a National Policy Framework for Artificial Intelligence” Executive Order was signed. This order calls for federal standards and legislation…

  • Disruptions caused by ongoing or future global conflicts, including those resulting from conflicts affecting or in close proximity to countries and regions in the Middle East, may result in extended lead times, delays in supplier deliveries, and increasing freight costs. The risk of supply disruptions may further result in delays in the delivery of our products.

  • In addition, once our devices are certified under the EU MDR, we must inform the notified body that carried out the conformity assessment of the medical devices that we market or sell in the EU and the EEA of any planned substantial changes to our quality system or substantial changes to our medical devices that could affect compliance with the general safety and performance requirements laid down in Annex I to the EU MDR or cause a substantial change to the intended use for which the device has been CE marked. The notified body will then assess the planned changes and verify whether they affect the products’ ongoing conformity with the EU MDR. If the assessment is favorable, the notified body will issue a new certificate of conformity or an addendum to the existing certificate attesting compliance with the general safety and performance requirements and quality system requirements laid…

  • In addition, the EU regulatory landscape concerning medical devices recently evolved and continues to undergo legislative changes. Read more

    On May 26, 2021, the EU MDR became applicable and repealed and replaced the EU MDD and the Active Implantable Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EU member states, regulations are directly applicable (i.e., without the need for adoption of EU member state laws implementing them) in all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The EU MDR, among other things, is intended to establish a uniform, transparent, predictable, and sustainable regulatory framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation. These requirements are in active implementation…

No longer in the text (4)

  • In Israel, we have certain research and development operations primarily related to digital products. Read more

    Depending on the length and extent of conflicts in the Middle East, including Israel and Iran, there may be adverse impacts to certain research and development timelines.

  • In the UK, following a national referendum and enactment of legislation by the government, the UK formally withdrew from the EU and ratified a trade and cooperation agreement governing its relationship with the EU. Read more

    The EU–UK Trade and Cooperation Agreement (the “TCA”) was applied provisionally as of January 1, 2021, and entered into force on May 1, 2021. The TCA does not specifically refer to medical devices. However, as a result of Brexit, the EU Medical Devices Regulation will not be implemented in the UK, and previous legislation that sought to mirror the EU Medical Devices Regulation in the UK law has been revoked. The regulatory regime for medical devices in Great Britain continues to be based on the requirements derived from previous EU legislation, and the UK may choose to retain regulatory flexibility or align with the EU Medical Devices Regulation going forward. On January 9,…

  • Pending such reform of the UK regulatory framework, the Government has confirmed that general medical devices compliant with the EU Medical Devices Directive with a valid declaration and CE marking can be placed on the Great Britain market up until the sooner of expiry of certificate or June 30, 2028. Medical devices, including custom-made devices, compliant with the EU Medical Devices Regulation can be placed on the Great Britain market up until June 30, 2030. The rules for placing medical devices on the market in Northern Ireland, which is part of the UK, differ from those in Great Britain (England, Scotland and Wales) and continue to be based on EU law. The TCA does provide for cooperation and exchange of information in the area of product safety and compliance, including market surveillance, enforcement activities and measures, standardization-related activities, exchanges of…

  • Additionally, in October 2023, armed conflict escalated between Israel and Hamas. Read more

    Hostilities between Israel and Hamas could persist, escalate, or expand to involve more countries and regions in the Middle East. As a result of such disruptions, we may experience in the future extended lead times, delays in supplier deliveries, and increased freight costs. The risk of ongoing supply disruptions may further result in delayed deliveries of our products.

7 more paragraphs differ; the filings below have the full text.

Matched automatically, quoted as filed, and may include rewording of an existing risk. Compares Item 1A of the 10-K filed Feb 3, 2026 ↗ with the 10-K filed Jan 31, 2025 ↗.

26

What to watch going forwardSite analysis

  • da Vinci 5 placements and procedure growth.
  • Court approval of the $450M antitrust settlement and the remanded SIS case.
  • Competition from new robotic systems, especially in China.
  • Buybacks.

27

Source documentsShow

This page's financial figures come from the Form 10-Ks listed below. Check the original filings for full detail.

Last updated

Analysis last edited: October 25, 2026 · Financial data fetched: October 25, 2026 14:17 (SEC EDGAR) · Source 10-K filed: February 3, 2026

Built on10-K FY2025 · filed 2026-02-03Proxy statement (2026)

Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.

This page is this site’s own analysis based on public information, and does not represent Intuitive Surgical’s views. It is not a recommendation to buy or sell any security, and this site does not guarantee the accuracy of any figure or statement here. Always verify against the original source documents before making an investment decision.